^
    Back
    Association details:
    Biomarker:TNFRSF8 expression
    Cancer:Peripheral T-cell Lymphoma
    Drug:acimtamig (AFM13) (CD16A agonist, CD30 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ICML 2023
    Title:

    AFM13 IN PATIENTS WITH CD30 POSITIVE RELAPSED OR REFRACTORY (R/R) PERIPHERAL T CELL LYMPHOMA (PTCL): RESULTS FROM THE PHASE 2 REDIRECT STUDY

    Published date:
    06/09/2023
    Excerpt:
    A Phase 2 study (NCT04101331) assessed the efficacy of AFM13 in patients with select R/R PTCL subtypes, exhibiting histologically confirmed CD30+expression in ≥1% tumor cells….AFM13 monotherapy demonstrated robust clinical activity in heavily pretreated patients with R/R PTCL.
    DOI:
    10.1002/hon.3163_126
    Trial ID:
    REDIRECT